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Abstract
Background: To evaluate the usefulness of this biomarker in the diagnosis of cases of cervical
neoplasia we studied the immunohistochemical expression of p16INK4a in a large series of archival
cervical biopsies arranged into tissue microarray format.
Methods:  TMAs were constructed with tissue cores from archival formalin fixed, paraffin-
embedded donor tissues from 796 patients, and included cases of cervical intraepithelial neoplasia
(CIN)1 (n = 249), CIN2 (n = 233), CIN3 (n = 181), and invasive cervical carcinoma (n = 133).
p16INK4a expression was scored using two different protocols: 1) positive vs negative p16INK4a
staining; 2) a semi-quantitative immunohistochemical score (0 to 8 points) according to the
intensity of staining and the proportion of stained cells
Results: p16INK4A expression was not seen in normal cervix tissue, but was found with increasing
frequency in the sequence: CIN1 (180/249; 72.3%) – CIN2 (212/233; 91.0%) – CIN3 (178/181;
98.3%) – invasive carcinoma (131/133; 98.5%). Using semi-quantitative scoring, all normal cervical
samples had low scores (from 0 to 2 points), whilst the number of specimens with high scores was
proportional to the degree of cervical dysplasia or the presence of invasive carcinoma.
Conclusion: Immunohistochemical analysis of p16INK4a expression is a useful diagnostic tool.
Expression is related to the degree of histological dysplasia, suggesting that it may have prognostic
and predicative value in the management of cervical neoplasia.
Background
Human papillomavirus (HPV) infection is a critical factor
in nearly all cases of cervical cancer [1-3]. Approximately
200 different subtypes of HPV have now been character-
ized, some of which carries a higher risk of cancer devel-
opment than others. The great majority of human cervical
cancers are associated with high-risk HPV infections,
although such infections result in progression to cervical
cancer in only a small percentage of infected women, and
typically only after a long latency period [4].
The intracellular targets for HPVs include a number of reg-
ulatory proteins such as cyclins, cyclin dependent kinases,
cyclin inhibitors, and cell cycle-associated proteins. The
HPV E6 and E7 oncoproteins inactivate the p53 and retin-
oblastoma protein (RB) tumor suppressors, respectively,
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leading to hyperproliferation and genomic instability [4-
7]. RB inhibits the progression of cells into S phase and is
regulated by cyclin D1 via phosphorylation. Progressive
and prolonged phosphorylation of the RB protein leads to
its inactivation and to a reduction of its growth suppres-
sive activity [7,8]. This inactivation is mediated by the
release of E2F-like transcription factors from RB, which
allows the activation of CDK and transcriptional activa-
tion of target promoters [9]. The CDKN2A gene product,
the p16INK4A protein, is a tumour suppressor protein that
inhibits CDK4 and CDK6, which phosphorylate the RB
protein. A reciprocal relationship between p16INK4A and
RB expression has been observed [10]. The p16INK4A gene
was found inactivated in a large percentage of tumor cell
lines, suggesting that it was indeed a tumor suppressor
gene [11-13].
p16INK4A overexpression has been demonstrated in cervi-
cal cancers as a result of functional inactivation of RB by
the HPV E7 protein [14]. It has been reported that the
HPV negative cell line C33A and HPV negative adenocar-
cinomas are p16INK4A positive, which indicates that a non-
HPV dependent p16INK4A expression pathway may also
exist [15,16].
A number of studies have demonstrated that p16INK4A
may be a useful marker for squamous and glandular epi-
thelial dysplasia in the uterine cervix [17,18]. Further-
more, expression of p16INK4A appears to correlate with the
degree of cervical neoplasia [19,20]. It was also recently
reported that p16INK4A immunostaining can be used for
discriminating integrated from non-integrated HPV infec-
tions [18,21].
Tissue microarray (TMA) is a well-established technology
for performing high-throughput gene expression analysis
in tissue sections [22]. In this technique, small cores of
formalin fixed paraffin embedded (FFPE) tissue are first
removed from a large number of "donor" paraffin blocks,
and then arrayed in a new "recipient" TMA. TMAs can con-
tain samples from hundreds of different donor speci-
mens, all of which can be stained simultaneously for a
particular marker in a single experiment using immuno-
histochemistry or in situ hybridization. In the previously
published TMA study of the uterine cervix, analysis of two
tissue cores from cases of cervical adenocarcinomas and
their pre-invasive precursors lesions in more than 95% of
cases gave data comparable with that obtained from stain-
ing a whole tissue section [23,24].
The present study was conducted in order to study the
immunohistochemical expression of p16INK4A in a large
number of archival sections of different degrees of precan-
cerous lesions and cervical cancer using tissue microarray
(TMA) technology and to find the optimal evaluation
method of p16INK4A expression for practical diagnostic
purposes.
Methods
Tissue processing and TMA preparation
Study cases were randomly selected from the archive of
the Institute of Pathology, Aarhus University Hospital. All
cases were routine diagnostic surgical specimens includ-
ing biopsies, loop, and cone excisions of the uterine cer-
vix, and hysterectomy sections. Tissues were fixed in
buffered formalin, processed using standard procedures
and embedded in paraffin. Tissue blocks were stored at
room temperature in the pathology archive up to 10 years
before being used for TMA construction. All specimens
were diagnosed by an experienced gynaecological pathol-
ogist according to World Health Organization classifica-
tion criteria. Only the samples that completely fulfilled
established diagnostic criteria were included in the study.
Tissue blocks containing only small or otherwise inade-
quate samples were excluded. In all, 796 specimens were
included in the study, comprising 249 cases of CIN1, 233
cases of CIN2, 181 cases of CIN3, and 133 cases of inva-
sive cervical carcinoma. The last group included 105 squa-
mous cell carcinomas (79%) and 28 adenocarcinomas
(21%) to represent the incidence of various degree of dys-
plasia and cancer in whole population. 10 samples of nor-
mal uterine cervix were used as a control.
Histological slides for each specimen included in the TMA
were reviewed, representative "donor" regions were iden-
tified under the microscope, and then these were marked
up with ink on each glass slide. Pilot TMAs were con-
structed in order to identify the optimal core diameter of
samples to be used. Cores with diameters of 0.6 mm, 1
mm, and 2 mm were compared with respect to ease of
TMS construction, ease of sectioning, and representativity
(data not shown). Cores of 1 mm diameter were chosen
for the project TMAs, as these proved easy to handle and
gave representative results compared with whole tissue
sections, TMAs were constructed using a manual Tissue
Arrayer (Beecher Instruments, Silver Spring, MD, USA)
essentially as described [22]. From the previously defined
area in the donor block, a 1 mm tissue cylinder was
punched out and transferred into the recipient block. In
some cases where the donor tissues were very thin, more
than one tissue cylinder was stacked in the same hole in
the recipient block. The number of cores used per case var-
ied from one to ten, depending upon the size of the region
of interest in each section. In the recipient block, cores
were arrayed according to a defined x-y coordinate posi-
tion. Normal liver and placenta tissue cores were used as
position markers at one corner of each TMA. After con-
struction, the TMA blocks were heated in an oven at 37°C
for 30 min and then at 60°C for 10 min. All blocks were
cut on a standard microtome. The 3 μm tissue sectionsDiagnostic Pathology 2009, 4:22 http://www.diagnosticpathology.org/content/4/1/22
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were floated in a 45°C water bath and collected on Super-
frost®  plus coated glass slides (Menzel-Gläser Gerhard
Menzel, Glasbearbeitungswerk GmbH & Co. KG – Saar-
brückener Str. 248 – D-38116 Braunschweig). Section cut-
ting proved to be a critical step in TMA production,
requiring considerable skill on the part of the microtome
operator in order to section successfully all the tissue spec-
imens in a TMA. Approximately 40 to 150 representative
sections could be cut from a TMA block depending upon
its size, the thickness of the donor tissues, and the experi-
ence of the operator.
Immunostaining for p16INK4A
p16INK4A was detected by immunohistochemistry using
monoclonal murine antibody clone JC8 (Biocompare
Inc., South San Francisco, CA 94080) on a BenchMark
Autostainer (Ventana Medical Systems, Illkirch, France).
Ready-to-use primary antibody optimally diluted accord-
ing to the manufacturer's recommendations was pur-
chased from Ventana Medical Systems. p16INK4A
expression was associated with distinct nuclear and cyto-
plasmic staining of epithelial cells and was evaluated
using two different scoring protocols: 1) Positive (moder-
ate or strong staining in more than 10% of epithelial cells)
vs negative (less than 10% of epithelial cells with moder-
ate or strong staining). 2) A semi-quantitative immuno-
histochemical score (0 to 8 points) depending on the
intensity (0 – 3 points; 0 – no staining; 1 – weak staining;
2 points – moderate staining; and 3 – strong staining) and
the proportion (0 – 5 points; 0 – no staining; 1 – <1% pos-
itive; 2 – 1% – 10% positive; 3 – 11% – 33% positive; 4 –
34% – 66% positive; and 5 – > 66% of positive) of stained
cells [25].
Non-parametric statistic tests for trend across ordered
groups were used.
Results
p16INK4A expression in epithelium was characterised by
variable, weak to strong, diffuse nuclear and cytoplasmic
staining. There was no difference in the intensity of stain-
ing between different epithelial layers. Clear and distinc-
tive positive staining was observed only in dysplastic cells.
Normal stromal and normal squamous epithelial cells
were consistently negative (Figure 1). In some normal
glandular epithelial cells diffuse weak or moderate stain-
ing was observed. We were not able to identify consistent
staining patterns that we believed could discriminate
between presumed integrated and non-integrated HPV.
Evaluation of p16INK4A immunostaining (see Figures 1 and 
Tables 1 and 2)
1. Simple (positive vs negative)
Overexpression of p16INK4A (moderate or strong staining
in more than 10% of epithelial cells) was seen in 72.3%
of CIN1, 91.0% of CIN2, 98.3% of CIN3, and 98.5% of
invasive cervical carcinomas (Table 1). All normal cervical
epithelium was 16INK4A negative.
2. Semi-quantitative scoring (0 – 8 points)
The distribution of p16INK4A scores in cervical specimens
with different grades of cervical neoplasia is shown in
Table 2. Normal cervical epithelium showed consistently
low immunohistological scores from 0 – 2. Specimens
with dysplastic cervical epithelium showed high immuno-
histological scores for p16INK4A, and these increased with
increasing CIN grade. The semi-quantitative scoring sys-
tem for p16INK4A expression was easy to perform, and it
gave a more detailed picture of the variable positive stain-
ing seen in neoplastic lesions. However, a small but defi-
nite minority of specimens with lower grades of dysplasia
had low or negative p16INK4A scores (0 – 2), comprising
some 9% of CIN1 and 5% of CIN2 lesions. Thus, also this
immunohistological score did not allow an absolute cut-
off point for p16INK4A expression in relation to dysplasia
or cancer to be identified, and the information obtained
using the more complex protocol was in principle no dif-
ferent to that obtainable with the more simple positive/
negative system of evaluation.
Using non-parametric statistic tests for trend across
ordered groups statistical significant differences (ρ ≤ 0.01)
between groups (normal tissue, CIN1, CIN2, CIN3 and
ICC) were found using both evaluation methods.
Discussion
We report the largest immunohistological study to date to
look at the association between p16INK4a expression and
cervical neoplasia. Immunohistological expression of
p16INK4a was seen only in dysplastic/neoplastic cells, and
was never observed in normal cervical epithelium. Thus,
p16INK4a expression appears to be a robust, specific and
sensitive biomarker of cervical neoplasia, confirming the
results of previous smaller series [17-20]. Although other
pathways cannot be ruled out, increased expression of
p16INK4a in the setting of CIN probably occurs mainly as a
result of inactivation of RB by high-risk HPVs. Circum-
stantial support for this premise comes from the observa-
tion that increasingly high p16INK4a expression scores were
seen in cervical specimens showing higher grades of CIN
or invasive carcinoma, lesions known to be closely associ-
ated with high-risk HPV infection.
Most cases of CIN1, and a large proportion of cases of
CIN2 and CIN3 can be expected to regress spontaneously
[26]. In many other cases, the grade of dysplasia will show
stable persistence. Thus, only a few percent of women
with CIN1 and CIN2 lesions, and only a slightly larger
minority of women with CIN3 will progress to develop
invasive cancer if left untreated. This emphasizes the needDiagnostic Pathology 2009, 4:22 http://www.diagnosticpathology.org/content/4/1/22
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Immunohistochemical analysis of p16INK4A expression using monoclonal antibody clone JC8 in tissue microarray cores from  cervix biopsies with normal epithelium (A, B), CIN1 (C, D), CIN2 (E, F), CIN3 (G, H) and invasive squamous carcinoma (I, J) Figure 1
Immunohistochemical analysis of p16INK4A expression using monoclonal antibody clone JC8 in tissue microar-
ray cores from cervix biopsies with normal epithelium (A, B), CIN1 (C, D), CIN2 (E, F), CIN3 (G, H) and inva-
sive squamous carcinoma (I, J). The normal epithelial and stromal cells are negative (A – B). Strong, distinct, diffuse staining 
of both nuclei and cytoplasm is seen in the dysplastic/neoplastic epithelium (C – J).Diagnostic Pathology 2009, 4:22 http://www.diagnosticpathology.org/content/4/1/22
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for predictive biomarkers that can identify those women
with cervical dysplasia who may be at risk of developing
higher grades of CIN or carcinoma. However, the picture
is further complicated by the fact that a large proportion
of women diagnosed with cervical carcinoma have not
previously had a preinvasive cervical lesion diagnosed. In
our database, only 9% of women with cervical carcinoma
had been previously registered with preinvasive cervical
lesions. This limits the ability to study the role of p16INK4a
expression as a predictive marker for the development of
invasive cancer, and even in the large series of cases
reported here we did not have enough cases with multiple
cervical biopsies to perform an analysis of p16INK4a expres-
sion in specimens from individual patients over time.
Whilst the association between increasing levels of
p16INK4a expression and higher grades of cervical dysplasia
was striking in our material, a small minority of cases with
CIN was negative for p16INK4a. Naturally, it would be of
value to know whether cases such as these would have
regressed spontaneously – i.e. whether p16INK4a expres-
sion is a predictive marker for progression in the cervix.
Unfortunately, this cannot be determined from our data.
Firstly, long-term patient follow up is not yet available on
our study cohort. Secondly, most of our study specimens
are removed as a part of the CIN treatment, biopsy being
followed by therapeutic ablation of the remaining dys-
plastic epithelium, thus changing the natural history of
the lesion.
The key differences between our study and similar previ-
ously reported IHC studies are firstly, the number of cases
analysed and secondly, the inclusion of large numbers of
premalignant intraepithelial cervical lesions. One advan-
tage of the TMA technique is that all samples are treated
with an identical staining protocol during analysis.
Clearly however, this uniformity at the staining stage can-
not compensate for analytical artefacts caused by eventual
differences in the tissue fixation (e.g. fixation type or dura-
tion) of the original donor tissues. This is also a potential
source of error when assessing whole tissue sections,
although in individual cases this can be allowed for (if
suspected) by subjecting parallel whole sections to differ-
ent antigen retrieval and staining protocols. In practice
however, this is difficult to apply to series of cases, and
would be logistically impossible in a study of 796 tissues
in whole sections. Fortunately, the high-throughput
nature of TMA technology can to a large extent allow for
errors such as those associated with differences in tissue
fixation and preparation, simply because these errors are
"diluted" by the size of the study cohort. TMAs can con-
tain samples from hundreds of different donor speci-
mens, all of which can be stained for a particular marker
in a single experiment. In addition to allowing efficient
high-throughput molecular profiling of large case-series,
Table 1: Immunohistochemical analysis of p16INK4A expression in 
tissue microarray cores from 806 cervix biopsies containing 
normal tissues, CIN1, CIN2, CIN3, and invasive cervical 
carcinoma (ICC), evaluated using the simple protocol.
p16INK4A immunostaining
n Negative* Positive#
Normal cervix 10 10 (100.0) 0 (0)
CIN1 249 69 (27.7) 180 (72.3)
CIN2 233 21 (9.0) 212 (91.0)
CIN3 181 3 (1.7) 178 (98.3)
ICC 133 2 (1.5) 131 (98.5)
*Negative: no staining or weak staining in less than 10% of epithelial 
cells.
#Positive: moderate or strong staining in more than 10% of epithelial 
cells.
Table 2: Immunohistochemical analysis of p16INK4A expression in tissue microarray cores from 806 cervix biopsies containing normal 
tissues, CIN1, CIN2, CIN3, and invasive cervical carcinoma (ICC), evaluated using the immunohistological score.
np 1 6 INK4A immunostaining*
023 45 6 7 8
Normal 10 7
(70.0)
3
(30.0)
0
(0)
0
(0)
0
(0)
0
(0)
0
(0)
0
(0)
CIN1 249 47
(18.9)
22
(8.8)
18
(7.2)
35
(14.1)
19
(7.6)
20
(8.0)
12
(4.8)
76
(30.5)
CIN2 233 10
(4,3)
11
(4.7)
14
(6.0)
15
(6.4)
13
(5.6)
18
(7.7)
7
(3.0)
145
(62.2)
CIN3 181 3
(1.7)
0
(0)
3
(1.7)
3
(1.7)
2
(1.1)
3
(1.7)
5
(2.8)
162
(89.5)
ICC 133 2
(1.5)
0
(0)
2
(1.5)
1
(0.8)
1
(0.8)
1
(0.8)
3
(2.3)
123
(92.5)
* Samples were assigned an immunohistological score (0 – 8) according to the intensity of staining and the proportion of stained cells in the cervical 
epithelium. The total score was the sum of score for stain intensity (0 – 3 points: 0 – no staining; 1 – weak staining; 2 points – moderate staining; 
and 3 – strong staining) and the score for propoertion of epithelial cells stained (0 – 5 points: 0 – no staining; 1 – <1% nuclei positive; 2 – 1% – 10% 
nuclei positive; 3 – 11% – 33% nuclei positive; 4 – 34% – 66% nuclei positive; and 5 – > 66% of nuclei positive).Diagnostic Pathology 2009, 4:22 http://www.diagnosticpathology.org/content/4/1/22
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the TMA technique has other advantages. All tissue sam-
ples within a TMA are analysed simultaneously using
identical reagents. By reducing the number of sections
examined, assay conditions can be more easily standard-
ised, reducing artefactual variation in staining and
improves the quality of data that can be obtained. Further-
more, since only a small part of each donor tissue block is
used in constructing the TMA, the technique helps to con-
serve scarce archival tissues for future studies. Our study
provides further evidence of the value of using TMAs
when performing gene expression analyses in large speci-
men cohorts in the search for novel diagnostic, prognostic
and predictive biomarkers.
The main potential disadvantage to using the TMA tech-
nique lies in the risk that the small sample used for con-
structing the TMA may not be representative of the whole
tissue section from the original specimen. This risk is
increased if the target molecule being analysed is only
rarely found within the study tissue, or shows an uneven
distribution in the tissue. Prior to our main study, we car-
ried out a pilot study comparing the effect of using multi-
ple cores and cores of different calibre on assay results
compared with whole sections (data not shown). We
established that 1 mm tissue cores from target lesions
were most appropriate for constructing our TMAs, com-
pared with 0.6 mm and 2 mm cores. This was a suitable
compromise, 1 mm cores being large enough to minimise
problems of poor representativity (compared with whole
sections) but small enough to allow high-density TMAs to
be constructed.
There is no agreement on the optimal protocol for evalu-
ating p16INK4A expression in the diagnostic setting. We
compared the use of a simple positive vs. negative score
with a more complex, but still easily applied semi-quanti-
tative immunohistological scoring system [25]. The latter
gave a more detailed picture of the spread of expression
scores and can be recommended for studies. However, the
two systems gave similar overall results, and the simpler
score appears to be quite adequate in a diagnostic setting.
Thus HPV positive tumours are characterized by high
expression of p16INK4A [19,27-30]. Moreover, since tran-
scription of the E7 oncogene is required for p16INK4A
upregulation, it has been suggested that carcinomas over-
expressing p16INK4A represent those tumours in which
HPV has been involved in the carcinogenic process [31].
Conclusion
We concluded that in large numbers of sections we were
able to prove that immunohistochemical detection
p16INK4a expression can be used as a specific diagnostic
marker of all degrees of cervical dysplasia and cervical can-
cer, and possibly as a surrogate marker for HPV infection,
due to the relationship between p16INK4A and HPV E7
inactivated RB protein. The simple scoring system of a
positive vs. a negative score seems to be adequate for prac-
tical diagnostic purposes.
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